Literature DB >> 24342167

Assessing the feasibility of volumetric-modulated arc therapy using simultaneous integrated boost (SIB-VMAT): An analysis for complex head-neck, high-risk prostate and rectal cancer cases.

Savino Cilla1, Francesco Deodato2, Cinzia Digesù2, Gabriella Macchia2, Vincenzo Picardi2, Marica Ferro2, Giuseppina Sallustio3, Marco De Spirito4, Angelo Piermattei4, Alessio G Morganti2.   

Abstract

Intensity-modulated radiotherapy (IMRT) allowed the simultaneous delivery of different doses to different target volumes within a single fraction, an approach called simultaneous integrated boost (SIB). As consequence, the fraction dose to the boost volume can be increased while keeping low doses to the elective volumes, and the number of fractions and overall treatment time will be reduced, translating into better radiobiological effectiveness. In recent years, volumetric-modulated arc therapy (VMAT) has been shown to provide similar plan quality with respect to fixed-field IMRT but with large reduction in treatment time and monitor units (MUs) number. However, the feasibility of VMAT when used with SIB strategy has few investigations to date. We explored the potential of VMAT in a SIB strategy for complex cancer sites. A total of 15 patients were selected, including 5 head-and-neck, 5 high-risk prostate, and 5 rectal cancer cases. Both a double-arc VMAT and a 7-field IMRT plan were generated for each case using Oncentra MasterPlan treatment planning system for an Elekta Precise linac. Dosimetric indexes for targets and organs at risk (OARs) were compared based on dose-volume histograms. Conformity index, homogeneity index, and dose-contrast index were used for target analyses. The equivalent uniform doses and the normal tissue complication probabilities were calculated for main OARs. MUs number and treatment time were analyzed to score treatment efficiency. Pretreatment dosimetry was performed using 2-dimensional (2D)-array dosimeter. SIB-VMAT plans showed a high level of fluence modulation needed for SIB treatments, high conformal dose distribution, similar target coverage, and a tendency to improve OARs sparing compared with the benchmark SIB-IMRT plans. The median treatment times reduced from 13 to 20 minutes to approximately 5 minutes for all cases with SIB-VMAT, with a MUs reduction up to 22.5%. The 2D-array ion-chambers' measurements reported an agreement of more than 95% for a criterion of 3% to 3mm. SIB-VMAT was able to combine the advantages of conventional SIB-IMRT with its highly conformal dose distribution and OARs sparing and the advantages of 3D-conformal radiotherapy with its fast delivery.
© 2013 Published by American Association of Medical Dosimetrists on behalf of American Association of Medical Dosimetrists.

Entities:  

Keywords:  Head-neck cancer; High-risk prostate cancer; Rectal cancer; SIB; VMAT

Mesh:

Year:  2013        PMID: 24342167     DOI: 10.1016/j.meddos.2013.11.001

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  8 in total

1.  Volumetric modulated arc therapy (VMAT) and simultaneous integrated boost in head-and-neck cancer: is there a place for critical swallowing structures dose sparing?

Authors:  Savino Cilla; Francesco Deodato; Gabriella Macchia; Cinzia Digesù; Anna Ianiro; Angelo Piermattei; Vincenzo Valentini; Alessio G Morganti
Journal:  Br J Radiol       Date:  2016-01-05       Impact factor: 3.039

2.  Automated hybrid volumetric modulated arc therapy (HVMAT) for whole-breast irradiation with simultaneous integrated boost to lumpectomy area : A treatment planning study.

Authors:  Savino Cilla; Carmela Romano; Gabriella Macchia; Mariangela Boccardi; Livia P De Vivo; Vittoria E Morabito; Milly Buwenge; Lidia Strigari; Luca Indovina; Vincenzo Valentini; Francesco Deodato; Alessio G Morganti
Journal:  Strahlenther Onkol       Date:  2021-11-12       Impact factor: 3.621

3.  Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy.

Authors:  Esengul Kocak-Uzel; G Brandon Gunn; Rivka R Colen; Micheal E Kantor; Abdallah S R Mohamed; Sara Schoultz-Henley; Paniyotis Mavroidis; Steven J Frank; Adam S Garden; Beth M Beadle; William H Morrison; Jack Phan; David I Rosenthal; Clifton D Fuller
Journal:  Radiother Oncol       Date:  2014-04-17       Impact factor: 6.280

Review 4.  Volumetric modulated arc therapy for treatment of solid tumors: current insights.

Authors:  Gabriella Macchia; Francesco Deodato; Savino Cilla; Silvia Cammelli; Alessandra Guido; Martina Ferioli; Giambattista Siepe; Vincenzo Valentini; Alessio Giuseppe Morganti; Gabriella Ferrandina
Journal:  Onco Targets Ther       Date:  2017-07-26       Impact factor: 4.147

5.  Assessment of multi-criteria optimization (MCO) for volumetric modulated arc therapy (VMAT) in hippocampal avoidance whole brain radiation therapy (HA-WBRT).

Authors:  Stephen Zieminski; Melin Khandekar; Yi Wang
Journal:  J Appl Clin Med Phys       Date:  2018-02-07       Impact factor: 2.102

6.  Partially ablative radiotherapy (PAR) for large mass tumors using simultaneous integrated boost: A dose-escalation feasibility study.

Authors:  Savino Cilla; Francesco Deodato; Anna Ianiro; Gabriella Macchia; Vincenzo Picardi; Milly Buwenge; Silvia Cammelli; Alice Zamagni; Vincenzo Valentini; Alessio G Morganti
Journal:  J Appl Clin Med Phys       Date:  2018-09-15       Impact factor: 2.102

7.  Post-Operative Accelerated-Hypofractionated Chemoradiation With Volumetric Modulated Arc Therapy and Simultaneous Integrated Boost in Glioblastoma: A Phase I Study (ISIDE-BT-2).

Authors:  Marica Ferro; Milena Ferro; Gabriella Macchia; Savino Cilla; Milly Buwenge; Alessia Re; Carmela Romano; Mariangela Boccardi; Vincenzo Picardi; Silvia Cammelli; Eleonora Cucci; Samantha Mignogna; Liberato Di Lullo; Vincenzo Valentini; Alessio Giuseppe Morganti; Francesco Deodato
Journal:  Front Oncol       Date:  2021-02-22       Impact factor: 6.244

8.  Personalized Treatment Planning Automation in Prostate Cancer Radiation Oncology: A Comprehensive Dosimetric Study.

Authors:  Savino Cilla; Carmela Romano; Vittoria E Morabito; Gabriella Macchia; Milly Buwenge; Nicola Dinapoli; Luca Indovina; Lidia Strigari; Alessio G Morganti; Vincenzo Valentini; Francesco Deodato
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.